5 04, 2022 Antonio Matrone et al., Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses adlitterio663392023-10-17T09:04:11+02:00 Mehr erfahren
26 03, 2022 Elisabetta Macerola et al., Down-regulation of miR-7-5p and miR-548ar-5p predicts malignancy in indeterminate thyroid nodules negative for BRAF and RAS mutations adlitterio663392022-10-20T12:31:05+02:00 Mehr erfahren
8 03, 2022 Théodora Mahoukèdè Zohoncon et al., Molecular Epidemiology of High-Risk Human Papillomavirus in High-Grade Cervical Intraepithelial Neoplasia and in Cervical Cancer in Parakou, Republic of Benin adlitterio663392022-10-20T13:59:09+02:00 Mehr erfahren
5 03, 2022 Maria Failla et al., A Case of Non-Irradiated Balloon Cell Melanoma of the Choroid: Expanding the Morphological Spectrum of Primary Uveal Melanomas adlitterio663392022-10-14T11:54:36+02:00 Mehr erfahren
13 11, 2021 Simona De Summa et al., A Promising Role of TGF-beta Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report adlitterio663392022-10-21T08:51:14+02:00 Mehr erfahren
3 11, 2021 Caterina De Luca et. al., RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer. Diatech Pharmacogenetics2021-11-03T17:22:38+01:00 Mehr erfahren
1 09, 2021 Carlotta Antoniotti et al., Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study adlitterio663392022-10-14T12:18:31+02:00 Mehr erfahren
23 08, 2021 Martina Lorenzi et al., First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. adlitterio663392021-08-23T12:10:15+02:00 Mehr erfahren
22 07, 2021 Alessandro Pancrazzi et al., Experience of Uncommon EGFR Mutation in Lung Scheme Quality Program: Discussing Risks and Opportunities for the Improvement of Laboratory Response adlitterio663392022-10-14T12:20:42+02:00 Mehr erfahren
1 07, 2021 Cristina Morelli et al., Perfect concordance between blood-based and normal tissue-based dihydropyrimidine dehydrogenase polymorphisms suggests that pharmacogenetic screening could be contextual to tumour molecular profiling adlitterio663392022-10-14T12:26:32+02:00 Mehr erfahren
